Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335


Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG.

J Clin Oncol. 2019 Jun 19:JCO1900107. doi: 10.1200/JCO.19.00107. [Epub ahead of print]


Prediction of significant estimated glomerular filtration rate decline after renal unit removal to aid in the clinical choice between radical and partial nephrectomy in patients with a renal mass and normal renal function.

McIntosh AG, Parker DC, Egleston BL, Uzzo RG, Haseebuddin M, Joshi SS, Viterbo R, Greenberg RE, Chen DYT, Smaldone MC, Kutikov A.

BJU Int. 2019 May 30. doi: 10.1111/bju.14839. [Epub ahead of print]


Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019.

Psutka SP, Chang SL, Cahn D, Uzzo RG, McGregor BA.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:276-283. doi: 10.1200/EDBK_237453. Epub 2019 May 17.


Editorial Comment.

Joshi SS, Uzzo RG.

Urology. 2019 Feb;124:165-167. doi: 10.1016/j.urology.2018.03.058. No abstract available.


Perioperative Statin Use and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy.

Joshi SS, Ruth K, Smaldone MC, Chen DYT, Greenberg RE, Viterbo R, Kutikov A, Uzzo RG.

Kidney Cancer. 2018 Mar 30;2(1):47-55. doi: 10.3233/KCA-180031.


Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group).

Anele UA, Marchioni M, Yang B, Simone G, Uzzo RG, Lau C, Mir MC, Capitanio U, Porter J, Jacobsohn K, de Luyk N, Mari A, Chang K, Fiori C, Sulek J, Mottrie A, White W, Perdona S, Quarto G, Bindayi A, Ashrafi A, Schips L, Berardinelli F, Zhang C, Gallucci M, Ramirez-Backhaus M, Larcher A, Kilday P, Liao M, Langenstroer P, Dasgupta P, Challacombe B, Kutikov A, Minervini A, Rha KH, Sundaram CP, Hampton LJ, Porpiglia F, Aron M, Derweesh I, Autorino R.

World J Urol. 2019 Feb 7. doi: 10.1007/s00345-019-02657-2. [Epub ahead of print]


Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.

Botejue M, Abbott D, Danella J, Fonshell C, Ginzburg S, Guzzo TJ, Lanchoney T, Marlowe B, Raman JD, Smaldone M, Tomaszewski JJ, Trabulsi EJ, Uzzo RG, Reese AC.

J Urol. 2019 May;201(5):929-936. doi: 10.1016/j.juro.2018.10.018.


A Return to the Days of Radical Nephrectomy as the "Gold Standard" for Localized Renal Cell Carcinoma? Not So Fast.

Derweesh IH, Staehler M, Uzzo RG.

Eur Urol. 2019 Apr;75(4):546-547. doi: 10.1016/j.eururo.2019.01.003. Epub 2019 Jan 14.


NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.

Pei J, Cooper H, Flieder DB, Talarchek JN, Al-Saleem T, Uzzo RG, Dulaimi E, Patchefsky AS, Testa JR, Wei S.

Mod Pathol. 2019 May;32(5):710-716. doi: 10.1038/s41379-018-0191-7. Epub 2019 Jan 8.


Author Response.

Correa AF, Uzzo RG.

Urology. 2019 Jan;123:179-180. doi: 10.1016/j.urology.2018.08.046. No abstract available.


Incisional hernia after cystectomy: incidence, risk factors and anthropometric predisposition.

Edwards DC, Cahn DB, Reddy M, Kivlin D, Malhotra A, Li T, Chen DYT, Viterbo R, Uzzo RG, Greenberg RE, Smaldone MC, Curcillo P, Kutikov A.

Can J Urol. 2018 Dec;25(6):9573-9578.


Application of Chromosome Microarray Analysis for the Differential Diagnosis of Low-grade Renal Cell Carcinoma With Clear Cell and Papillary Features.

Pei J, Al-Saleem T, Uzzo RG, Dulaimi E, Testa JR, Wei S.

Appl Immunohistochem Mol Morphol. 2018 Nov 28. doi: 10.1097/PAI.0000000000000704. [Epub ahead of print]


Assessment of volume preservation performed before or after partial nephrectomy accurately predicts postoperative renal function: Results from a prospective multicenter study.

Klingler MJ, Babitz SK, Kutikov A, Campi R, Hatzichristodoulou G, Sanguedolce F, Brookman-May S, Akdogan B, Capitanio U, Roscigno M, Volpe A, Marszalek M, Uzzo RG, Antonelli A, Langenhuijsen J, Carini M, Minervini A, Lane BR.

Urol Oncol. 2019 Jan;37(1):33-39. doi: 10.1016/j.urolonc.2018.11.007. Epub 2018 Nov 23.


Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?

Haas NB, Uzzo RG.

J Clin Oncol. 2018 Oct 29:JCO2018789131. doi: 10.1200/JCO.2018.78.9131. [Epub ahead of print]


Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer.

Liao L, Liu ZZ, Langbein L, Cai W, Cho EA, Na J, Niu X, Jiang W, Zhong Z, Cai WL, Jagannathan G, Dulaimi E, Testa JR, Uzzo RG, Wang Y, Stark GR, Sun J, Peiper S, Xu Y, Yan Q, Yang H.

Elife. 2018 Oct 25;7. pii: e37925. doi: 10.7554/eLife.37925.


Renal Hilar Lesions: Biological Implications for Complex Partial Nephrectomy.

Correa AF, Yankey H, Li T, Joshi SS, Kutikov A, Chen DY, Viterbo R, Greenberg RE, Smaldone MC, Uzzo RG.

Urology. 2019 Jan;123:174-180. doi: 10.1016/j.urology.2018.08.044. Epub 2018 Oct 6.


Does the Surgical Apgar Score predict serious complications after elective major cancer surgery?

Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF.

J Surg Res. 2018 Nov;231:242-247. doi: 10.1016/j.jss.2018.05.037. Epub 2018 Jun 23.


Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.

Ristau BT, Handorf EA, Cahn DB, Kutikov A, Uzzo RG, Smaldone MC.

Cancer. 2018 Oct 1;124(19):3839-3848. doi: 10.1002/cncr.31582. Epub 2018 Sep 12.


Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.

Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM.

Mol Cancer Ther. 2018 Jul;17(7):1355-1364. doi: 10.1158/1535-7163.MCT-17-1299. Review.


Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.

Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM.

Eur Urol. 2018 Sep;74(3):387-393. doi: 10.1016/j.eururo.2018.05.025. Epub 2018 Jun 5.


The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass.

Shah PH, Alom MA, Leibovich BC, Thompson RH, Uzzo RG, Kavoussi LR, Richstone L, Bhindi B, Habermann EB, Joshi V, Boorjian SA.

J Urol. 2018 Nov;200(5):981-988. doi: 10.1016/j.juro.2018.05.081. Epub 2018 May 22.


Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group).

Bertolo R, Autorino R, Simone G, Derweesh I, Garisto JD, Minervini A, Eun D, Perdona S, Porter J, Rha KH, Mottrie A, White WM, Schips L, Yang B, Jacobsohn K, Uzzo RG, Challacombe B, Ferro M, Sulek J, Capitanio U, Anele UA, Tuderti G, Costantini M, Ryan S, Bindayi A, Mari A, Carini M, Keehn A, Quarto G, Liao M, Chang K, Larcher A, De Naeyer G, De Cobelli O, Berardinelli F, Zhang C, Langenstroer P, Kutikov A, Chen D, De Luyk N, Sundaram CP, Montorsi F, Stein RJ, Haber GP, Hampton LJ, Dasgupta P, Gallucci M, Kaouk J, Porpiglia F.

Eur Urol. 2018 Aug;74(2):226-232. doi: 10.1016/j.eururo.2018.05.004. Epub 2018 May 19.


Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes.

McIntosh AG, Ristau BT, Ruth K, Jennings R, Ross E, Smaldone MC, Chen DYT, Viterbo R, Greenberg RE, Kutikov A, Uzzo RG.

Eur Urol. 2018 Aug;74(2):157-164. doi: 10.1016/j.eururo.2018.03.011. Epub 2018 Apr 4.


Comparison of functional outcomes of robotic and open partial nephrectomy in patients with pre-existing chronic kidney disease: a multicenter study.

Hamilton ZA, Uzzo RG, Larcher A, Lane BR, Ristau B, Capitanio U, Ryan S, Dey S, Correa A, Reddy M, Proudfoot JA, Nasseri R, Yim K, Noyes S, Bindayi A, Montorsi F, Derweesh IH.

World J Urol. 2018 Aug;36(8):1255-1262. doi: 10.1007/s00345-018-2261-3. Epub 2018 Mar 12.


The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma.

Makhov P, Naito S, Haifler M, Kutikov A, Boumber Y, Uzzo RG, Kolenko VM.

Cell Death Dis. 2018 Mar 7;9(3):374. doi: 10.1038/s41419-018-0388-1.


Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis.

Joshi SS, Handorf E, Strauss D, Correa AF, Kutikov A, Chen DYT, Viterbo R, Greenberg RE, Uzzo RG, Smaldone MC, Geynisman DM.

JAMA Oncol. 2018 May 1;4(5):643-649. doi: 10.1001/jamaoncol.2017.5608.


Discrimination of malignant and normal kidney tissue with short wave infrared dispersive Raman spectroscopy.

Haifler M, Pence I, Sun Y, Kutikov A, Uzzo RG, Mahadevan-Jansen A, Patil CA.

J Biophotonics. 2018 Jun;11(6):e201700188. doi: 10.1002/jbio.201700188. Epub 2018 May 16.


The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma.

Mehrazin R, Dulaimi E, Uzzo RG, Devarjan K, Pei J, Smaldone MC, Kutikov A, Testa JR, Al-Saleem T.

Ther Adv Urol. 2017 Oct 31;10(1):3-10. doi: 10.1177/1756287217732660. eCollection 2018 Jan.


Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database.

Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC.

J Urol. 2018 May;199(5):1238-1244. doi: 10.1016/j.juro.2017.11.121. Epub 2017 Dec 15.


A structured framework for optimizing surgical quality through process-of-care trials.

Waingankar N, Esnaola NF, Uzzo RG.

Urol Oncol. 2017 May;35(5):177-179. doi: 10.1016/j.urolonc.2017.03.017. Epub 2017 Apr 18.


Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer.

Dong Y, Zaorsky NG, Li T, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MA, Horwitz EM.

J Med Imaging Radiat Oncol. 2018 Feb;62(1):116-121. doi: 10.1111/1754-9485.12675. Epub 2017 Oct 13.


Latent Class Survival Models Linked by Principal Stratification to Investigate Heterogenous Survival Subgroups Among Individuals With Early-Stage Kidney Cancer.

Egleston BL, Uzzo RG, Wong YN.

J Am Stat Assoc. 2017;112(518):534-546. doi: 10.1080/01621459.2016.1240078. Epub 2016 Oct 7.


External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy.

Haifler M, Ristau BT, Higgins AM, Smaldone MC, Kutikov A, Zisman A, Uzzo RG.

J Urol. 2018 Mar;199(3):649-654. doi: 10.1016/j.juro.2017.09.070. Epub 2017 Sep 20.


Race and postoperative complications following urologic cancer surgery: An ACS-NSQIP analysis.

Parker DC, Handorf E, Smaldone MC, Uzzo RG, Pitt H, Reese AC.

Urol Oncol. 2017 Dec;35(12):670.e1-670.e6. doi: 10.1016/j.urolonc.2017.08.001. Epub 2017 Sep 1.


Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis.

Cahn DB, Handorf E, Ristau BT, Geynisman DM, Simhan J, Kutikov A, Greenberg RE, Viterbo R, Chen DYT, Uzzo RG, Smaldone MC.

Urol Oncol. 2017 Dec;35(12):670.e15-670.e21. doi: 10.1016/j.urolonc.2017.07.026. Epub 2017 Aug 10.


Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.

Cahn DB, Handorf EA, Ghiraldi EM, Ristau BT, Geynisman DM, Churilla TM, Horwitz EM, Sobczak ML, Chen DYT, Viterbo R, Greenberg RE, Kutikov A, Uzzo RG, Smaldone MC.

Cancer. 2017 Nov 15;123(22):4337-4345. doi: 10.1002/cncr.30900. Epub 2017 Jul 25.


Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG.

J Urol. 2018 Jan;199(1):53-59. doi: 10.1016/j.juro.2017.07.042. Epub 2017 Jul 18.


Active Surveillance for Small Renal Masses: When Less is More.

Ristau BT, Kutikov A, Uzzo RG, Smaldone MC.

Eur Urol Focus. 2016 Dec 15;2(6):660-668. doi: 10.1016/j.euf.2017.04.004. Epub 2017 Apr 19. Review.


Role of collaboration between urologists and medical oncologists in the advanced prostate cancer space.

Ramamurthy C, Doyle J, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM.

Urol Oncol. 2017 Dec;35(12):665-669. doi: 10.1016/j.urolonc.2017.06.046. Epub 2017 Jul 15. No abstract available.


Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.

Judd J, Zibelman M, Handorf E, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman J, Borghaei H, Plimack ER, Mehra R, Geynisman DM.

Oncologist. 2017 Oct;22(10):1232-1237. doi: 10.1634/theoncologist.2017-0133. Epub 2017 Jun 26.


Management of the Incidental Renal Mass on CT: A White Paper of the ACR Incidental Findings Committee.

Herts BR, Silverman SG, Hindman NM, Uzzo RG, Hartman RP, Israel GM, Baumgarten DA, Berland LL, Pandharipande PV.

J Am Coll Radiol. 2018 Feb;15(2):264-273. doi: 10.1016/j.jacr.2017.04.028. Epub 2017 Jun 23.


WBC Associates with Readmission Following Cystectomy.

McIntosh AG, Li T, Ito T, Mannion J, Dziemianowicz M, Waingankar N, Haseebuddin M, Chen DYT, Greenberg RE, Viterbo R, Kutikov A, Uzzo RG, Smaldone MC, Abbosh PH.

Bladder Cancer. 2017 Apr 27;3(2):95-103. doi: 10.3233/BLC-160088.


Renal Mass and Localized Renal Cancer: AUA Guideline.

Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, Clark PE, Davis BJ, Derweesh IH, Giambarresi L, Gervais DA, Hu SL, Lane BR, Leibovich BC, Pierorazio PM.

J Urol. 2017 Sep;198(3):520-529. doi: 10.1016/j.juro.2017.04.100. Epub 2017 May 4.


Active Surveillance for the Small Renal Mass: Growth Kinetics and Oncologic Outcomes.

Ristau BT, Correa AF, Uzzo RG, Smaldone MC.

Urol Clin North Am. 2017 May;44(2):213-222. doi: 10.1016/j.ucl.2016.12.007. Epub 2017 Mar 14. Review.


Renal Tumor Anatomic Complexity: Clinical Implications for Urologists.

Joshi SS, Uzzo RG.

Urol Clin North Am. 2017 May;44(2):179-187. doi: 10.1016/j.ucl.2016.12.004. Epub 2017 Mar 14. Review.


Combination of serum histidine and plasma tryptophan as a potential biomarker to detect clear cell renal cell carcinoma.

Lee HO, Uzzo RG, Kister D, Kruger WD.

J Transl Med. 2017 Apr 6;15(1):72. doi: 10.1186/s12967-017-1178-8.


LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma.

Naito S, Makhov P, Astsaturov I, Golovine K, Tulin A, Kutikov A, Uzzo RG, Kolenko VM.

Br J Cancer. 2017 Apr 25;116(9):1203-1207. doi: 10.1038/bjc.2017.77. Epub 2017 Mar 28.


Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.

Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK.

JAMA Oncol. 2017 Sep 1;3(9):1249-1252. doi: 10.1001/jamaoncol.2017.0076.


The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.

Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM.

Can J Urol. 2017 Feb;24(1):8656-8662.


Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.

Shaikh T, Li T, Handorf EA, Johnson ME, Wang LS, Hallman MA, Greenberg RE, Price RA Jr, Uzzo RG, Ma C, Chen D, Geynisman DM, Pollack A, Horwitz EM.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):722-731. doi: 10.1016/j.ijrobp.2016.12.034. Epub 2016 Dec 28.

Supplemental Content

Support Center